DexCom has done a decent job managing its cost base over the last five years. The company has produced an average operating margin of 14.4%, higher than the broader healthcare sector. Looking at ...

Investors with significant funds have taken a bearish position in DexCom (NASDAQ:DXCM), a development that retail traders should be aware of. This was brought to our attention today through our ...

underscoring operational and cost challenges faced by the company. The quarter featured significant strategic moves, including the submission of the Dexcom G7 15-day CGM system to the FDA.

My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 earnings release conference call. All lines ...